pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,002 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1782Endpoints1389Fierce Biotech708BioSpace698BioPharma Dive524raps234onclive165fda recalls113fda medwatch
therapy area
allOncology12306Rare Disease3217Immunology2862Cardiology2745Hematology2177Pulmonology2138Vaccines
  • Stage IV Breast Cancer Cases Rise Over Past Decade, Dana-Farber Study Shows
    A recent analysis by Dana-Farber Cancer Institute examined breast cancer diagnoses over the past ten years. The researchers found that the number of patients diagnosed with stage IV disease has ri…
    onclive · 6mo agoNeutral↗ source
  • Biogen reports mixed results in mid‑stage trial of tau‑targeting Alzheimer’s therapy
    Biogen disclosed data from a Phase 2 study of its experimental Alzheimer’s drug that targets the tau protein. The trial showed a combination of positive and negative signals, with some measures ind…
    STAT · 6mo agoNegative readoutNeutral↗ source
← prev
page 106 of 121
next →
111
globenewswire health73
fda press59
1796
Psychiatry & CNS1204
Ophthalmology1060
Pain777
Endocrinology & Metabolism776
Nephrology760
  • Experts anticipate Daraxonrasib and new GI cancer therapies at ASCO 2026
    Ahead of the 2026 ASCO Annual Meeting, leading oncologists and researchers focusing on gastrointestinal cancers highlighted the topics they expect to dominate the conference. Central among the buz…
    onclive · 6mo agoNeutral↗ source
  • Triplet immunotherapy improves survival in HER2‑positive gastric cancer, suggesting broader immune activation
    New data from a study of HER2‑positive gastric cancer patients evaluated a triplet immunotherapy regimen. The analysis compared the combination against standard approaches and focused on overall su…
    onclive · 6mo agoPositive readoutPositive↗ source
  • Zenidatamab regimens show survival benefit in HER2-positive gastric cancer, but PD-L1 test variability raises treatment questions
    The HERIZON‑GEA‑01 study reports that zenidatamab‑based treatment schedules lead to a notable improvement in overall survival for patients with HER2‑positive gastric cancer. These efficacy finding…
    onclive · 6mo agoPositive readoutPositive↗ source
  • CREATE Medicines raises $122 million to advance CAR-T candidates into human trials
    CREATE Medicines, formerly Myeloid Therapeutics, announced a $122 million financing round. The funding came from Newpath Partners, ARCH Venture Partners, Hatteras Venture Partners and other invest…
    STAT · 6mo agoDealPositive↗ source
  • Acting FDA Commissioner Kyle Diamantas Seen as Drama-Free Stabilizer for Biotech
    Kyle Diamantas has been named the acting commissioner of the Food and Drug Administration, stepping into the role after Marty Makary’s resignation. He previously led the FDA’s food safety division,…
    STAT · 6mo agoRegulatoryPositive↗ source
  • Dr. Jones reports GLP-1 agonists may outperform aspirin in colorectal cancer prevention and tolerability
    Dr. Colton Jones presented findings from a retrospective analysis that compared GLP-1 receptor agonists with aspirin for primary prevention of colorectal cancer. The analysis indicated that patien…
    onclive · 6mo agoPositive readoutPositive↗ source
  • FDA searches for new commissioner as Marty Makary departs, Trump administration outlines priorities
    Marty Makary is leaving his role at the FDA, as reported in STAT’s D.C. Diagnosis newsletter. The Trump administration has released a lengthy wish list for the next FDA commissioner, indicating th…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • STAT launches investigative series on alcohol epidemic killing 178,000 Americans annually
    STAT has begun a new investigative series that examines the United States’ ongoing alcohol crisis, which the outlet says results in roughly 178,000 deaths each year. The reporting team traveled na…
    STAT · 6mo agoNegative↗ source
  • STAT+: CDC plans to transfer monkeys to nonprofit’s sanctuary as it seeks to reduce animal testing
    The CDC intends to transfer more than 160 macaques to Born Free USA, a nonprofit that runs a large primate sanctuary in Texas, as the agency seeks to phase out…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Major digital health firms stay out of Medicare's chronic care ACCESS pilot
    The latest STAT Health Tech newsletter reports that the biggest players in digital health are not participating in Medicare's ACCESS pilot, a program designed to test chronic-care solutions for Med…
    STAT · 6mo agoNeutral↗ source
  • Understanding MET Alterations in Non‑Small Cell Lung Cancer and Emerging Targeted Treatment Options
    The article outlines the primary MET alterations observed in non‑small cell lung cancer, focusing on gene amplification and exon 14 skipping mutations. It explains that these MET changes frequentl…
    onclive · 6mo agoNeutral↗ source
  • Alcohol treatment sees growing shift toward alternatives beyond Alcoholics Anonymous
    The article highlights a growing movement away from traditional Alcoholics Anonymous programs toward newer, more flexible approaches for treating alcohol use disorder. It notes that many patients a…
    STAT · 6mo agoNeutral↗ source
  • Experts discuss ongoing challenges and emerging options for treating anemia in myelofibrosis
    Anemia frequently accompanies myelofibrosis and can worsen fatigue and overall prognosis. Clinicians often struggle to manage this complication effectively. In a recent discussion, Dr. Aaron Gerds…
    onclive · 6mo agoNeutral↗ source
  • REVELUTION-2 trial assesses cardiovascular safety of relugolix plus abiraterone in high‑risk prostate cancer
    The REVELUTION-2 study is focused on measuring the heart‑related risks associated with a hormone‑therapy regimen that combines relugolix and abiraterone acetate in patients with high‑risk prostate…
    onclive · 6mo agoNeutral↗ source
  • TROP2 scoring and MTAP loss emerge as key biomarkers for NSCLC treatment decisions
    Researchers are highlighting two molecular features-TROP2 expression and loss of the MTAP enzyme-as potential guides for therapy in non‑small cell lung cancer. Quantitative scoring of TROP2 by pat…
    onclive · 6mo agoNeutral↗ source
  • Three years of falling overdose deaths spark cautious optimism amid lingering concerns
    Over the past three years, the United States has seen a steady decline in overdose deaths, a trend that has generated cautious optimism among public‑health observers. While the numbers are encourag…
    STAT · 6mo agoPositive↗ source
  • Physician warns AI could undermine authentic care in addiction treatment
    Physician Steve D. Klein, an addiction medicine specialist, argues that recent AI tools marketed for addiction care miss the core of patient treatment. He describes seeing a prototype that, while t…
    STAT · 6mo agoNegative↗ source
  • Dr. Hunter outlines anemia treatment options for myelofibrosis patients
    Dr. Anthony M. Hunter, a hematology specialist, discussed how clinicians approach anemia in patients with myelofibrosis. He highlighted luspatercept as one therapeutic option, noting its mechanism…
    onclive · 6mo agoNeutral↗ source
  • Key AUA 2026 abstracts to watch: immunotherapy for NMIBC and radioligand therapy for mHSPC
    The American Urological Association 2026 meeting will feature several highly anticipated abstracts. Experts say immunotherapy for non‑muscle‑invasive bladder cancer is a major focus, reflecting gr…
    onclive · 6mo agoNeutral↗ source
  • Experts clarify differences between glioblastoma and diffuse midline glioma under 2021 WHO classification
    In the opening episode of their series, Dr. Shonka and Dr. Chong introduce a discussion about two distinct diseases that both carry the name glioma. They explain that glioblastoma and diffuse midl…
    onclive · 6mo agoNeutral↗ source
  • Case Introduction Highlights ctDNA as Emerging Risk Factor
    The article presents a case introduction that focuses on circulating tumor DNA (ctDNA) as a potential emerging risk factor. It outlines the relevance of ctDNA in assessing disease risk, emphasizin…
    onclive · 6mo agoNeutral↗ source
  • MRI Features That Suggest Diffuse Midline Glioma Highlighted in Expert Discussion
    In a recent educational segment, Dr. Chong introduced the clinical scenario where patients with suspected brain tumors are first evaluated with imaging before tissue sampling. He then asked Dr. Sh…
    onclive · 6mo agoNeutral↗ source
  • MIT reports 10% drop in research output and 20% fall in graduate admissions amid funding and immigration challenges
    MIT President Sally Kornbluth announced that the institute's research enterprise is 10% smaller than a year ago. The university also said graduate admissions for the 2026-2027 year are down 20%, c…
    STAT · 6mo agoNegative↗ source